NCT03717415
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Tyrosine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only TNBC patients are eligible for Part 2 (dose expansion phase)
Exclusions: Patients with known active CNS metastases
https://ClinicalTrials.gov/show/NCT03717415